Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma (VOR)
NASDAQ:VOR
VOR Stock Chart & Stats
$15.90
<$0.01(<0.01%)
At close: 4:00 PM EST
$15.90
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)782.72K
Market Cap
$637.33M
Enterprise Value-$47.33M
Total Cash (Recent Filing)$170.46M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)―
Beta4.98
Next Earnings
Mar 19, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-121.63
Shares Outstanding41,519,840
10 Day Avg. Volume554,270
30 Day Avg. Volume782,715
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.01
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$45.33Price Target Upside185.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data StrengthTelitacicept has produced promising clinical results in China for myasthenia gravis and Sjögren’s disease, providing supportive efficacy evidence that could bolster broader global development plans.
Global Commercialization StrategyVor Biopharma's license to commercialize telitacicept outside China from RemeGen establishes a clear pathway to pursue international markets if global regulatory approvals are secured.
Valuation RecognitionAnalysts note a significant valuation disconnect in Vor Biopharma shares based on the probability-adjusted value of telitacicept in myasthenia gravis and primary Sjögren’s disease, indicating potential upside as late-stage data gain recognition.
Bears Say
Data Dependency And Market ReactionMuted market responses to China-only trial disclosures and the requirement for successful phase 3 readouts outside China for US, EU and Japan approvals could constrain near-term stock upside.
Financing RiskThe company will likely need additional financing to fund global development beyond China, and the current cash position could remain a sentiment overhang until funding is secured.
Pipeline Concentration RiskHeavy reliance on a single drug candidate creates material risk for shares until independent global data validate the therapeutic's performance across major markets.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $637.33M.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is Mar 19, 2026 which is in 20 days.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on Nov 13, 2025. The company reported -$121.63 earnings per share for the quarter, missing the consensus estimate of -$3.452 by -$118.178.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate is -1.02.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 41,519,840 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of -$121.63 in its last earnings report, missing expectations of -$3.452. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Vor Biopharma?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.33 (185.09% Upside)
$45.33 (185.09% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.94%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$45.33
▲(185.09% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---